Early intravenous unfractionated heparin and mortality in septic shock

被引:99
作者
Zarychanski, Ryan [1 ,2 ,3 ]
Doucette, Steven [3 ]
Fergusson, Dean [3 ]
Roberts, Daniel [1 ]
Houston, Donald S. [2 ]
Sharma, Satendra [1 ]
Gulati, Harlena [4 ]
Kumar, Anand [1 ,5 ]
机构
[1] Univ Manitoba, Sect Crit Care Med, Winnipeg, MB, Canada
[2] Cancercare Manitoba, Dept Hematol & Med Oncol, Winnipeg, MB, Canada
[3] Ottawa Hlth Res Ctr, Ottawa, ON, Canada
[4] Univ Manitoba, Dept Anesthesia, Winnipeg, MB, Canada
[5] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp, Univ Med Ctr,Sect Cardiovasc Dis & CCM, Camden, NJ 08103 USA
关键词
anticoagulants; heparin; mortality; sepsis; septic shock;
D O I
10.1097/CCM.0b013e31818b8c6b
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Sepsis and septic shock represent a systemic inflammatory state with substantial pro-coagulant elements. Unfractionated heparin is a known anticoagulant, which also possesses anti-inflammatory properties. Unfractionated heparin has been shown to increase survival in experimental models of septic shock. Objective: To evaluate the impact of intravenous therapeutic dose unfractionated heparin in a cohort of patients diagnosed with septic shock. Design: Retrospective, propensity matched, multicenter, cohort study. Setting. Regional intensive care units in Winnipeg, Canada between 1989 and 2005. Patients: Two thousand three hundred fifty-six patients diagnosed with septic shock, of which 722 received intravenous therapeutic dose heparin. Measurements and Main Results. The primary outcome of study was 28-day mortality, and mortality stratified by severity of illness (Acute Physiologic and Chronic Health Evaluation 11 quartile). Safety was assessed by comparing rates of gastrointestinal hemorrhage, intracranial hemorrhage, and the need for transfusion. By using a Cox proportional hazards model, systemic heparin therapy was associated with decreased 28-day mortality (307 of 695 [44.2%] vs. 279 of 695 [40.1%]; hazard ratio 0.85 [confidence interval (CI) 95% 0.73-1.00]; p = 0.05). In the highest quartile of severity of illness (Acute Physiologic and Chronic Health Evaluation 11 score 29-53), heparin administration was associated with a clinically and statistically significant reduction in 28-day mortality [127 of 184 (69.0%) vs. 94 of 168 (56.0%); hazard ratio 0.70 (CI 95% 0.54-0.92); p = 0.01]. The use of intravenous unfractionated heparin was associated with successful liberation from mechanical ventilation [odds ratio of 1.42 (Cl 95% 1.13-1.80); p = 0.003], and successful discontinuation of vasopressor/inotropic support [odds ratio of 1.34 (CI 95% 1.06-1.71); p = 0.01]. No significant differences in the rates of major hemorrhage or need for transfusion were identified. Conclusion: Early administration of intravenous therapeutic dose unfractionated heparin may be associated with decreased mortality when administered to patients diagnosed with septic shock, especially in patients with higher severity of illness. Prospective randomized trials are needed to further define the role of this agent in sepsis and septic shock. (Crit Care Med 2008; 36: 2973-2979)
引用
收藏
页码:2973 / 2979
页数:7
相关论文
共 38 条
[1]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[3]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[4]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]  
BRESLOW NW, 1980, I AGENCY RES CANCER, V32, P138
[7]   INCIDENCE, RISK-FACTORS, AND OUTCOME OF SEVERE SEPSIS AND SEPTIC SHOCK IN ADULTS - A MULTICENTER PROSPECTIVE-STUDY IN INTENSIVE-CARE UNITS [J].
BRUNBUISSON, C ;
DOYON, F ;
CARLET, J ;
DELLAMONICA, P ;
GOUIN, F ;
LEPOUTRE, A ;
MERCIER, JC ;
OFFENSTADT, G ;
REGNIER, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (12) :968-974
[9]   The effectiveness of right heart catheterization in the initial care of critically ill patients [J].
Connors, AF ;
Speroff, T ;
Dawson, NV ;
Thomas, C ;
Harrell, FE ;
Wagner, D ;
Desbiens, N ;
Goldman, L ;
Wu, AW ;
Califf, RM ;
Fulkerson, WJ ;
Vidaillet, H ;
Broste, S ;
Bellamy, P ;
Lynn, J ;
Knaus, WA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (11) :889-897
[10]   EFFECT OF HEPARIN IN EXPERIMENTAL GRAM-NEGATIVE SEPTICEMIA [J].
CORRIGAN, JJ ;
KIERNAT, JF .
JOURNAL OF INFECTIOUS DISEASES, 1975, 131 (02) :138-143